中国药物警戒2024,Vol.21Issue(6) :625-631.DOI:10.19803/j.1672-8629.20240149

细胞因子释放综合征的体外试验探索性研究

Exploratory study of cytokine release syndrome in vitro

傅盈双 李双星 姜华 屈哲 霍桂桃 杨艳伟 张頔 黄瑛 李波 林志
中国药物警戒2024,Vol.21Issue(6) :625-631.DOI:10.19803/j.1672-8629.20240149

细胞因子释放综合征的体外试验探索性研究

Exploratory study of cytokine release syndrome in vitro

傅盈双 1李双星 1姜华 1屈哲 1霍桂桃 1杨艳伟 1张頔 1黄瑛 1李波 1林志1
扫码查看

作者信息

  • 1. 国家药物安全评价监测中心,药物非临床安全性评价研究北京市重点实验室,中国食品药品检定研究院安全评价研究所,北京 100176
  • 折叠

摘要

目的 建立细胞因子释放综合征(CRS)的体外评价方法,对试验体系细胞密度、阳性药种类及浓度进行探索.方法 分别用CD3抗体(OKT3)(0.1~5 μg)、OKT3(0.1~1 μg)+CD28抗体(anti-CD28)(1、2 μg·mL-1)、佛波酯(PMA)(10~100 ng·mL-1)、PMA(10~100 ng·mL-1)+离子霉素(ION)(1、5 μg·mL-1)刺激外周血单个核细胞(PBMC)48 h,用CCK-8 法检测细胞增殖情况来筛选PBMC的最佳密度及药物的最佳浓度.实验分为 7 组:对照组、OKT3 0.1 μg+anti-CD28 1 μg·mL-1 组、OKT3 0.5 μg+anti-CD28 1 μg·mL-1 组、OKT3 1 μg+anti-CD28 1 μg·mL-1 组、PMA 10 ng·mL-1+ION 1 μg·mL-1 组、PMA 25 ng·mL-1+ION 1 μg·mL-1 组、PMA 50 ng·mL-1+ION 1 μg·mL-1组,分别与PBMC细胞暴露 48 h,收集细胞上清,通过酶联免疫吸附试验(ELISA)检测药物作用下PBMC释放细胞因子白介素-6(IL-6)、干扰素γ(IFN-γ)情况.结果 与对照组相比,OKT3 和PMA均引起中密度、高密度PBMC显著增殖,各剂量OKT3 和PMA均引起细胞增殖.与阳性药单独使用相比,药物联合使用产生更强的细胞活化效应.与对照组相比,在OKT3(0.1~1 μg)+anti-CD28(1 μg·mL-1)作用下,PBMC释放IL-6、IFN-γ显著增加;在PMA(10~50 ng·mL-1)+ION(1 μg·mL-1)作用下,PBMC分泌IFN-γ与对照组相比显著增加,在PMA(25~50 ng·mL-1)+ION(1 μg·mL-1)作用下,PBMC分泌IL-6与对照组相比显著增加.结论 确定了PBMC体外CRS风险评价方法的细胞密度、阳性药物种类及浓度、药物联合使用浓度.

Abstract

Objective To establish an in vitro evaluation method of cytokine release syndrome(CRS),and explore the cell density,positive drug types and concentrations of the test system.Methods Peripheral blood mononuclear cells(PBMC)were stimulated with CD3 antibody(OKT3)(0.1~5μg),OKT3(0.1~1μg)+CD28 antibody(anti-CD28)(1 and 2 μg·mL-1),phorbol-12-myristate-13-acetate(PMA)(10~100 ng·mL-1),and PMA(10~100 ng·mL-1)+ionomycin(ION)(1 and 5 μg·mL-1)for 48 h,respectively.The proliferation of PBMC was assessed by the CCK-8 method to determine the optimal cell density and drug concentration.There were seven groups in the experiment:Control group,OKT3 0.1μg+anti-CD28 1 μg·mL-1 group,OKT3 0.5μg+anti-CD28 1μg·mL-1 group,OKT3 1μg+anti-CD28 1μg·mL-1 group,PMA 10 ng·mL-1+ION 1μg·mL-1 group,PMA 25 ng·mL-1+ION 1μg·mL-1 group and PMA 50 ng·mL-1+ION 1μg·mL-1 group.The cell supernatant was collected after 48 h of exposure to the respective treatments and cytokine IL-6 and IFN-γ was detected by ELISA.Results Compared with the control group,both OKT3 and PMA induced significant proliferation of medium density and high density PBMC,and OKT3 and PMA induced cell proliferation at all doses.The combination of drugs produced a stronger cell activation effect than the positive drug alone.Compared with the control group,the release of IL-6 and IFN-γ from PBMC was significantly increased under OKT3(0.1~1μg)+anti-CD28(1μg·mL-1)treatment.Under PMA(10~50 ng·mL-1)+ION(1μg·mL-1),the secretion of IFN-γ by PBMC was significantly increased compared with the control group,and under PMA(25-50 ng·mL-1)+ION(1μg·mL-1),the secretion of IL-6 by PBMC was significantly increased compared with the control group.Conclusion The study determines the cell density,positive drug types and concentrations,and drug combination of CRS risk assessment methods for PBMC in vitro.

关键词

细胞因子释放综合征/CD3单克隆抗体/CD28抗体/佛波酯/离子霉素/外周血单个核细胞/细胞密度

Key words

cytokine release syndrome/orthoclone/CD28 antibody/phorbol-12-myristate-13-acetate/ionomycin/peripheral blood mononuclear cell/cell density

引用本文复制引用

基金项目

国家重点研发计划(2021YFA1101602)

中国食品药品检定研究院学科带头人课题项目(2023X3)

出版年

2024
中国药物警戒
国家药品监督管理局药品评价中心(国家药品不良反应监测中心)

中国药物警戒

CSTPCD
影响因子:1.105
ISSN:1672-8629
段落导航相关论文